Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers

NCT05749549 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Follicular Lymphoma
Peripheral T Cell Lymphoma
Diffuse Large B Cell Lymphoma

Interventions

DRUG: BR1733

Sponsor

Shanghai Blueray Biopharma Co., Ltd.